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Colitis, idiopathic bowel diseases (IBDs)
Patients with chronic IBDs commonly present with intestinal motility 
complications. When the gut is inflamed, breakdown of the intestinal barrier 
function, abnormal secretion and changes in the patterns of motility and 
visceral sensation all contribute to symptom generation (Lakhan 2010). 
Inflammation affects not only the mucosa, but extends to the deeper layers of 
the intestinal wall, causing alterations in nitrergic (Tomita 1998), adrenergic 
and glutamatergic neurotransmission (Zhou 2006, Kaszaki 2011) and in smooth 
muscle contractility. The experimental data suggest that inflammation, even if 
mild, could lead to persistent changes in gastrointestinal (Gl) function, 
resulting in colonic dysmotility and hypersensitivity, even when the preceding 
infection is restricted to the proximal small intestine. The roles of gaseous and 
humoral mediators, including nitric oxide (NO), tumor necrosis factor-alpha 
(TNF-a) and other cytokines have been widely investigated in this condition 
(Neurath 1997; Tomita 1998; Lindsay 2002). Moreover, it has been revealed 
that inflammatory alterations in gut function are accompanied by significant 
changes in activity of the glutamate receptors, which have important roles in 
the intrinsic neuronal control of Gl motility (Kirchgessner 2001).
Glutamate in the enteral nervous system (ENS)
Glutamate immunoreactivity was first detected in subsets of 
submucosal and myenteric neurones in the guinea-pig ileum (Moroni 1986). It 
was subsequently shown that glutamate is selectively concentrated in terminal 
axonal vesicles and can be released after an appropriate stimulus, and 
functional studies demonstrated the significance of glutamate in the 
modulation of motor and secretory functions in the gut (Wiley 1991). 
Glutamate neurotoxicity (necrosis and apoptosis) was later observed in enteric 
neurons in both intact bowel preparations and cultured myenteric ganglia
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(Kirchgessner 2001). It has therefore been suggested that excitotoxicity and 
overactivation of the enteric glutamate receptors may contribute to 
inflammation-induced intestinal damage.
N-Methyl-D-aspartate (NMDA) receptors: motility regulation and 
inflammation. The receptors that mediate the glutamate signal are divided 
into two main classes, which can be subdivided according to the 
pharmacological agents capable of specifically activating the appropriate 
receptor. The ionotropic receptors, such as the kainate, alpha-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionic acid and NMDA receptors, are ligand­
gated ion channels, while the metabotropic receptors are coupled to G- 
proteins. Ionotropic NMDA-sensitive glutamate receptors are present and 
abundantly expressed on enteric cholinergic neurons (Moroni 1986; Wiley 
1991).The Gl motility response basically depends on the outcome of myenteric 
plexus activation, and the net effect combines contractile and relaxant signals. 
The participation of peripheral NMDA glutamate receptors in this mechanism 
is of special interest, but the exact mediatory pathways and the 
neurotransmitters released concomitantly have not yet been fully elucidated. 
Recent studies suggest that hyperalgesia in colitis is caused by the enhanced 
activity of NMDA receptors in the spinal nociceptive pathways and on the 
peripheral (Zhou 2006) and central ends of primary afferent neurons (Li 2006). 
More importantly, other in vivo data have indicated that the expression of 
NMDA receptors is enhanced in peripheral inflammatory reactions (Tan 2008) 
and receptor up-regulation occurs on the neurons of the myenteric plexus in 
TNBS-induced colitis too (Zhou 2006).
It has been postulated that nitrergic neurotransmission, one of the 
forms of intrinsic innervation, mediates peristaltic waves, inhibitory responses 
or relaxing mechanisms of the Gl tract (Ekblad 1994, Kohjitani 2005). Our 
earlier data led to the conclusion that NO may play a complex role in the 
regulation of the motility of the inflamed colon: NO of neuronal origin is a 
transmitter that stimulates the peristaltic activity of the colon, since 
nonselective NO synthase (NOS) inhibition gave rise to a transient inhibition of 
the motility, whereas the administration of a selective neuronal NOS inhibitor 
elicited long-lasting motility inhibition (Palasthy 2006). It seems reasonable 
that activation of the myenteric NMDA receptors, followed by a massive Ca2+
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influx through the NMDA receptor-ion complex, may stimulate NO synthesis, 
which would result in turn in colonic smooth muscle relaxation.
In contrast, several studies have indicated that NMDA induces 
contraction of the ileal smooth muscle (Moroni 1986). It should be added that 
the'* formation of reactive oxygen species (ROS) during the inflammatory 
procer may provide an explanation for this finding. Superoxide production 
has been demonstrated to be triggered by NMDA activation and the reaction is 
inhibited by superoxide dismutase (Lafon-Cazal 1993). Xanthine 
oxidoreductase (XOR)-dependent ROS production is known to occur in the 
early phase of colon obstruction and also during experimental colitis (Kaszaki 
2008; Varga 2010). NO in combination with XOR-derived superoxide radicals 
leads to the formation of peroxynitrite, a well-known inhibitor of NOS activity 
and highly injurious to a variety of cells (Beckman 1990). The enhanced 
production of peroxynitrite and the decreased NOS activity eliminate the 
relaxant effect of endogenous NO. Taken together, the excessive accumulation 
of glutamate with subsequent activation of the ligand-gated, ion channel 
NMDA receptors opposes the NO-dependent relaxation (Kohjitani 2005).
NMDA receptor antagonism
Kynurenic acid (KynA), one of the few known endogenous excitatory 
amino acid receptor blockers, has high affinity for the glycine coagonist site of 
the NMDA receptors and a broad spectrum of antagonistic properties in 
supraphysiological concentrations (Sas 2007). It is a product of an alternative 
tryptophan metabolism, the kynurenine pathway, which is the major route for 
the conversion of tryptophan to NAD and NADP, leading to the production of a 
number of biologically active molecules with neuractive properties. KynA is 
able to reduce the excitotoxic damage to the CNS (Choi 1988) and it is 
additionally effective against neurodegenerative disorders (Klivényi 2004).
NMDA antagonism: experimental results
An important feature of KynA is its ability to reduce inflammatory 
reactions in the colon (Varga 2010). In our studies, we employed haptene- 
induced rat colitis, a frequently used IBD model. In animal experiments, 2,4,6- 
trinitrobenzensulfonic acid (TNBS) is an appropriate substance with which to 
model the symptoms of human colitis and to test new therapeutic possibilities. 
A single intracolonal (ic) TNBS enema causes extensive transmural colitis with
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ulcerations that last longer than 8 weeks. As compared with the control group, 
rats with TNBS colitis exhibit a weight loss (Morris 1989), visceral hyperalgesia 
(Zhou 2008), significant elevations of plasma TNF-a, tissue NOS and XOR 
activities (Varga 2010) and leukocyte accumulation, as evidenced by increased 
level of myeloperoxidase (MPO) activity. In our first study series, the animals 
were anesthetized with sodium pentobarbital (50 mg/kg bw ip), and 
macrohemodynamic parameters, including mean arterial pressure (MAP), 
heart rate (HR) and cardiac output (CO; by a thermodilution technique) were 
recorded with a SPEL Advanced Cardiosys 1.4 computer (Experimetria Ltd., 
Budapest, Hungary). After a midline abdominal incision, a strain gauge 
transducer (Experimetria Ltd., Budapest, Hungary) was sutured onto the colon 
wall 3 cm distal from the cecum for the measurement of colonic motility. At 
the end of the experiments, blood samples were taken for the determination 
of TNF-a concentrations, while the XOR and MPO activities and extent of NO 
production [the level of nitrite/nitrate (NOx), stable end-products of NO] were 
measured in colonic tissue biopsies (Varga 2010).
Table 1.
Effects of synthetic KynA derivatives (KADs) on hemodynamic, motility, and
biochemical parameters.____________________
Groups Mol. Hemodynamic Motility Biochemical
(n=5-10) weight parameters parameters parameters
SZR-72 295.7 - -
KAD-79 337.8 41 41 tr
KAD-80 335.8 -a tr tr
KAD-81 321.8 - 41 tr
KAD-82 323.8 tr 41 -
KAD-83 351.8 - tl -
KAD-100 356.5 - - tT
K AD-101 382.2 tr tr tr
K AD-104 358.2 - - tr
KAD-105 384.2 tr 41 41
KAD-106 342.2 - -
KAD-107 368.2 - tr tr
KAD-108 344.2 41 41 tr
KAD-761 286.3 - - tr
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With this model, we tested a variety of synthetic KynA derivatives 
(KADs) containing different side-chain modifications (the analogs were 
synthetized by the Institute of Pharmaceutical Chemistry, University of Szeged) 
48 h after colitis induction and the data were compared with the results on the 
untreated control group (Table 1). Compounds with macrohemodynamic side- 
effects (unwanted MAP, CO or HR changes) or dysmotility were then excluded, 
and finally two KynA analogs (SZR-72 and KAD-106) were chosen for further 
examinations. In these subgroups, the motility inhibitory potential and anti­
inflammatory effects of the KADs were analyzed in a subacute TNBS-induced 
colitis model.
The animals received enemas in a total volume of 0.25 ml, containing 
only the solvent (25% ethanol) in the case of the sham-operated group, or 34 
mg TNBS for the other 3 groups, 17 h before the start of monitoring. The next 
day, the animals were anesthetized and surgery was performed to monitor the 
hemodynamics and colonic motility for 6 h. The groups treated with the KADs 
received an iv infusion containing 10 mg kg 1 SZR-72, or 11.5 mg kg'1 KAD-106 
(equimolar doses) dissolved in 0.9% saline with the pH adjusted to 7.2-7.4 in a 
total volume of 1 ml. The 30-min treatments started 18 h after the ic 
instillation of TNBS. At the end of the experiments, full-thickness tissue 
samples were taken to determine the colonic MPO and XOR activities and level 
of NO production. The plasma TNF-a concentration was determined in venous 
blood samples with an ELISA kit (Biomedica Hungaria Kft, Hungary).
As compared with the baseline values there were no significant 
changes in the hemodynamic parameters in the sham-operated group during 
the observation period. The CO was significantly higher in the colitis groups 
than in the sham-operated group, while both KADs reduced the increased CO, 
though the effect of SZR-72 lasted longer. There were no differences in HR or 
MAP between the groups.
To estimate the excitatory status of the ENS, the motility index 
(determined via the area under the motility curve) was calculated as a marker 
of the condition of neuronal control. At the beginning of the observation 
period, the motility index was higher in the TNBS-treated groups than in the 
sham-operated animals and it remained significantly higher throughout the 
later phase of the experiments. SZR-72 decreased the motility index
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significantly, whereas KAD-106 treatment did not cause a significant decrease 
in motility index, though a decreasing tendency was observed (Figure 1).
Time (h)
F ig .l. Changes in colon motility index in the sham-operated (shaded squares with a thin 
continuous line), colitis (black diamonds with a thick line), SZR-72 (empty triangles with a thick 
line) and KAD-106-treated colitis (empty circles with a thick line) groups. The box indicates the 
time of treatment with synthetic NMDA antagonist. The plots depict the median values and 
the 25th (lower whisker) and 75th (upper whisker) percentiles. * p<0.05 within groups vs 
baseline values, x p<0.05 between groups vs sham-operated group values.
Data relating to the anti-inflammatory capabilities of the KADs are 
presented in Table 2. The plasma TNF-a concentration and tissue XOR and 
MPO activities were increased significantly in the proximal colon as compared 
with those in the sham-operated group 23 h after colitis induction. Both SZR- 
72 and KAD-106 induced a significant decrease in the MPO activity of the large 
bowel relative to the non-treated colitis group, and the SZR-72 treatment 
significantly decreased the TNF-a level and XOR activity too. Activation of the 
NMDA receptors and subsequent NO production may be the key in both 
motility and local inflammation changes. This study revealed that the TNBS- 
induced mucosal damage was associated with a significant increase in colonic 
NOx level. The SZR-72 treatment decreased NO production significantly, while 
KAD-106 administration did not significantly influence the elevated colonic 
NOx level as compared with that in the colitis group.
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Table 2.
Effects of colitis and NMDA antagonism on colon myeloperoxidase (MPO) 
activity [U *(m g*proteincolon xanthine oxidoreductase (XOR) activity 
[(pmol*(min*mg)_1)], plasma nitrite/nitrate level (NOx) [pmol] and plasma
TNF-ct levels (ng ml'1).
MPO XOR NO* TNF-a
Sham-operated Median 0.725 24.8 15.59 3.48
25p; 75p 0.67; 0.883 21.75; 27.5 14.59; 15.97 1.24; 8.76
Colitis Median 1.41 x 44.2 x 18.81 x 13.82 x
25p; 75p 1.101; 1.651 73.6; 48.43 17.37; 20.29 10.39; 18.06
Colitis+SZR-72 Median 0.924# 18.3# 16.31 # 7.27
25p; 75p 0.876; 1.002 15.53; 22.18 14.24; 16.65 4.09; 10.24
Colitis+KAD-106 Median 0.438 # 34.6 x + 15.94 12.54 x
25p; 75p 0.27; 0.589 30.43; 39.75 13.24; 18.62 11.98; 13.99
xp  < 0.05 relative to the sham-operated group; Up < 0.05 relative to the colitis 
group;
+ p<  0.05 relative to the colitis+SZR-72 group
In summary, our results have demonstrated an important role of 
NMDA receptor activation in the pathophysiology of TNBS-induced colitis. 
Neuroprotection is a therapeutic strategy aimed at slowing or halting the 
progression of primary neuronal loss following acute or chronic diseases. The 
KynA analog SZR-72 significantly inhibited the colon motility, and also exerted 
a potentially protective, anti-inflammatory effect due to the inhibition of XOR 
activity, colonic NO production and concomitant leukocyte accumulation in the 
inflamed tissues. KAD-106 administration likewise resulted in significant, but 
moderate anti-inflammatory effects in the TNBS-induced colitis model. It 
remains to be established whether the findings in this experimental model are 
applicable to humans. However, together with previous observations, the 
present data suggest that inhibition of the enteric NMDA receptors may 
provide a novel neuroprotective option via which to influence intestinal 
hypermotility and inflammatory processes simultaneously.
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